• diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;

• presence of PVTT with III-IV grade by Cheng's criteria;

• having PVTT induced portal hypertension;

• TIPS was performed within 72 hours after the endoscopic hemostasis;

• metastases with limited five sites and no more two organs involved;

• number of Intrahepatic tumors were no more than five;

• receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy;

• classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;

• no history of other malignancies;

⁃ agreed to participated in this clinical trial;

⁃ Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.